Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode

SUPPLEMENTARY DATA SUPPLEMENTARY MATERIALS AND METHODS
Synthesis procedure
All solvents and reagents were used as obtained. 1 H NMR spectra and 13 C NMR spectra were recorded with a Bruker 400 NMR spectrometer and referenced to deuterium dimethyl sulfoxide (DMSO-d 6 ) or deuterium chloroform (CDCl 3 ). Chemical shifts are expressed in ppm. In the NMR tabulation, s indicates singlet; d, doublet; t, triplet; q, quartet; m, multiplet; and br, broad peak. LC/MS experiments were performed on an Agilent 6224 TOF using an ESI source coupled to an Agilent 1260 Infinity HPLC system operating in reverse mode with an Agilent Eclipse Plus C18 1.8 μm, 3.0 mm × 50 mm column. Purification of final compounds were performed with Isco CombiFlash Rf + system (silica flash column 4 g) using a gradient of 0−10% MeOH in DCM over 20 min at a flow rate of 18 mL/min. The purities of all compounds were above 95% (Supplementary Figure 1) [1] .
2-((4-bromo-2-chlorophenoxy)methyl)-6-methylpyridine (S1) The mixture of 4-bromo-2-chlorophenol (2.0 g, 9.7 mmol), 2-(bromomethyl)-6-methylpyridine (1.8 g, 9.7 mmol) and K 2 CO 3 (1.3 g, 9.7 mmol) in DMF (10 mL) was stirred at room temperature for 2 h. The resulting mixture was diluted with 100 mL of EtOAc, then washed with water (3 × 50 mL) followed by brine. The organic layers were dried over sodium sulfate, filtered, and concentrated to provide S1 as an a light yellow solid (2.0 g, 66.7%) without further purification.
1 H NMR (400 MHz, DMSO-d 6 ) δ 7.80 -7.62 (m, 2H), 7.47 (d, J = 5.9 Hz, 1H), 7.33 (s, 1H), 7.18 (d, J = 8.1 Hz, 2H), 5.23 (s, 2H), 2.48 (s, 3H); 13 C NMR (100 MHz, DMSO-d 6 ) δ 158. 02, 155.70, 153.48, 137.75, 132.46, 131.48, 123.33, 122.84, 118.69, 116.39, 112.63, 71.67, 24.37 2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenoxy)methyl)-6-methylpyridine (S2) To a solution of S1 (1.5 g, 4.8 mmol) in 1,4-dioxane (15 mL) were added bis(pinacolato)diboron (1.3 g, 5.3 mmol), KOAc (1.0 g, 9.6 mmol), and Pd(dppf)Cl 2 (0.19 g, 0.24 mmol) at room temperature. The reaction mixture was stirred overnight at 100 °C under argon protection. 02, 156.37, 155.77, 137.75, 136.12, 135.28, 122.81, 121.82, 118.65, 116.34, 114.23, 84.25, 71.33, 25.07, 24.36 . The reaction mixture was placed into an oil bath preheated to 90 °C, with stirring at this temperature for 12 h under argon. The resulting mixture was then concentrated to afford the crude product, which was purified by silica gel column chromatography (eluting with 0−2% MeOH in DCM) to provide the desired Boc-protected monoamine as an off-white solid (0.9 g). Then to the solid in EtOAc (3 mL) was added 4 N HCl in EtOAc (12 mL). The reaction mixture was stirred at room temperature for 1 h. After complete conversion of the starting material, excess EtOAc was removed under vacuum. The residue was diluted in EtOAc and water. The water layer was basified with 2 N NaHCO 3 solution and extracted with EtOAc (3 × 70 mL). The organic layers were then washed with water followed by brine. The organic layers were dried over sodium sulfate, filtered, and concentrated to provide S4 as an off-white solid (0.39 g, 60.0%) without further purification. 1 68, 158.06, 155.97, 155.92, 154.21, 154.17, 142.33, 137.84, 130.15, 128.74, 122.88, 122.48, 118.75, 115.09, 97.83, 71.64, 54.35, 51.16, 45.82, 30.67, 26.36, 24.40 03, 158.71, 158.04, 156.14, 155.91, 154.45, 154.24, 142.81, 137.79, 130.19, 128.73, 127.87, 127.65, 127.11, 122.84, 122.53, 118.71, 115.04, 97.90, 71.65, 53.18, 52.48, 49.72, 46.19, 45.66, 42.10, 30.07, 29.80, 25.35, 24.39, 23.70 -1-(3-(4-amino-3-(3-chloro-4-((6-methylpyridin-2-yl) 
2-((
